ArticleScience translational medicine2022
Genomic and epigenomic
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 49 citations in OpenAlex.
- Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.British journal of cancer · 2026Trial
- Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors.International journal of radiation oncology, biology, physics · 2025Trial
- Epigenetic Plasticity in Triple-Negative Breast Cancer: Mechanisms of Therapy Resistance, Biomarkers, and Therapeutic Vulnerabilities.Biomedicines · 2026Review
- HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Estrogen receptor-positive, BRCA1-deficient breast cancer: BRCA1-epimutated tumors presenting a piece to the puzzle.Breast cancer research : BCR · 2026Review
- Prevalence ofJCO precision oncology · 2026Article
- 5mC and 5hmC methylation sequencing: the power of 6-base sequencing in a multiomic era.Epigenomics · 2026Review
- Breast Cancer Disparities in African and African-Ancestry Populations: Genetics, Epigenetics, Structural Barriers and Technology-Enabled Solutions.British journal of biomedical science · 2026Review
- Prediction of neoadjuvant therapy response in breast cancer based on interpretable artificial intelligence.International journal of surgery (London, England) · 2026Article
- Decoding BRCA1 promoter hypermethylation: a new frontier in understanding sporadic breast cancer.Cancer gene therapy · 2025Article
- Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy forInternational journal of molecular sciences · 2025Review
- The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer.Cancers · 2025Review
- BRCA1 promoter methylation predicts PARPi response in ovarian cancer: insights from the KOMET study.Clinical epigenetics · 2025Article
- Epigenetic evolution and clinicopathological implications of distinct DNA methylation profiles in pancreatic ductal adenocarcinoma.Scientific reports · 2025Article
- Advances in tumor subclone formation and mechanisms of growth and invasion.Journal of translational medicine · 2025Review
- Constitutional Epimutations: From Rare Events Toward Major Cancer Risk Factors?JCO precision oncology · 2025Review
- Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses.bioRxiv : the preprint server for biology · 2025Article
- Patient-Derived Xenografts of Breast Cancer.Advances in experimental medicine and biology · 2025Review
- Mechanisms of tandem duplication in the cancer genome.DNA repair · 2025Review
- Molecular Subgroups of HRD Positive Ovarian Cancer and Their Prognostic Significance.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Francesca MenghiJackson Laboratory for Genomic Medicine, Farmington, CT 06030, USA.ORCID 0000-0002-7209-251X
Kalyan BandaDivision of Medical Oncology, UW Medical Center, Seattle, WA 98195, USA.ORCID 0000-0003-2581-6906
Pooja KumarJackson Laboratory for Genomic Medicine, Farmington, CT 06030, USA.ORCID 0000-0002-6589-2447
Robert StraubJackson Laboratory for Genomic Medicine, Farmington, CT 06030, USA.ORCID 0000-0002-3444-4158
Lacey DobroleckiLester and Sue Smith Breast Center, Houston, TX 77030, USA.ORCID 0000-0001-6839-629X
Isabel V RodriguezDepartment of Obstetrics and Gynecology, UW Medical Center, Seattle, WA 98195, USA.ORCID 0000-0002-5113-6173
Susan E YostDivision of Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.ORCID 0000-0002-9422-0316
Harshpreet ChandokJackson Laboratory for Genomic Medicine, Farmington, CT 06030, USA.
Marc R RadkeDepartment of Obstetrics and Gynecology, UW Medical Center, Seattle, WA 98195, USA.ORCID 0000-0003-0983-7838
George SomloDivision of Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Yuan YuanDivision of Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.ORCID 0000-0001-7440-8939
Michael T LewisDepartments of Molecular and Cellular Biology and Radiology, Lester and Sue Smith Breast Center, Dan L Duncan Comprehensive Cancer Center, Houston, TX 77030, USA.
Elizabeth M SwisherDepartment of Obstetrics and Gynecology, UW Medical Center, Seattle, WA 98195, USA.
Edison T LiuJackson Laboratory for Genomic Medicine, Farmington, CT 06030, USA.ORCID 0000-0003-4293-4795
Jackson Laboratory · USUniversity of Washington Medical Center · USCity of Hope · USSmiths Detection (Canada) · CAThe University of Texas MD Anderson Cancer Center · US
Funding
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3MShared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9MTranslational Research in Breast Cancer (SPORE)P50CA186784 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MATTHEW J ELLIS · 2014 to 2026
$24.5MResearch Project 2 - Targeting Melanoma Tumor Survival and Apoptotic MachineryU54CA224070 · NCI · WISTAR INSTITUTE · PI Michael Davies · 2017 to 2026
$13.9MTolinapant efficacy in a subset of triple negative breast cancersU54CA224076 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Michael T. Lewis · 2017 to 2026
$13.5MGenomic Biology of the Tandem Duplicator Phenotype in Mouse and Human CancersR01CA255705 · NCI · JACKSON LABORATORY · PI LIU, EDISON TAK-BUN · 2021 to 2025
$3.5MINTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCERU24CA226110 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LEWIS, MICHAEL T., RUBIN, DANIEL L · 2019 to 2023
$3.2MCombined Methylation and Mutation to Predict Response to PARP InhibitorsR01CA237600 · NCI · UNIVERSITY OF WASHINGTON · PI SWISHER, ELIZABETH MARY · 2020 to 2024
$2.9MNCI NIH HHS P30 CA033572NCI NIH HHS P30 CA034196NCI NIH HHS P50 CA186784NCI NIH HHS R01 CA237600NCI NIH HHS R01 CA255705NCI NIH HHS U24 CA226110NCI NIH HHS U54 CA224070NCI NIH HHS U54 CA224076
Abstract
Triple-negative breast cancer (TNBC) and ovarian carcinomas (OvCas) with
Indexed as
CarcinomaOvarian NeoplasmsTriple Negative Breast NeoplasmsBRCA1 ProteinBRCA2 ProteinEpigenomicsFemaleGenomicsHumansMutationPlatinumBRCA1 ProteinBRCA2 ProteinPlatinum
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.